Suven Pharmaceuticals expects multiple products to come in via Casper Pharma, Venkat Jasti, chairman and managing director, told CNBC-TV18.
The company has acquired Casper Pharma for Rs 155 crore.
He said, “Casper Pharma is awaiting for US FDA inspection in next 3-6 months, filed abbreviated new drug applications (ANDAs) and have a long-term contract with US distributor for next 7 years. So a lot of products will be coming in.”
“All the products will have manufactured and supplied on a profit-sharing basis and that’s the rationale with which we have bought,” said Jasti.
The company has paid only for the cost of the facility, he said.
For the entire interview, watch the accompanying video